<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Provedano, Santiago Tofé</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Dulaglutide Noninferior to Liraglutide for Glycemic Control in Patients with T2DM</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses the results from the Assessment of Weekly Administration of LY2189265 in Diabetes-6 [AWARD-6; NCT01624259] trial, which show that once-weekly dulaglutide provides glycemic control that is noninferior to once-daily liraglutide with a similar safety and tolerability profile.</style></abstract><number><style face="normal" font="default" size="100%">32</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>